Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure Post author: Post published:September 3, 2024 Post category:uncategorized MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients. You Might Also Like Vitamin D monitoring during pregnancy and postpartum April 1, 2025 Discovery of gene variant could transform treatment for newborn jaundice September 17, 2024 COVID-19 testing and variants more prevalent in minority communities October 9, 2024